Dopamine Detours: Exploring Innovative Neurotransmitter Targets in the Treatment of Schizophrenia
Released On
December 20, 2024
Expires On
December 20, 2025
Media Type
Internet
Completion Time
45 minutes
Specialty
Neurology, Primary Care, Psychiatry
Topics
Schizophrenia, Mental Health
Provider Statement
This activity is provided by Integrity CE, LLC.
Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Credit Available
- Physicians - maximum of 0.75 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of US-based psychiatrists, primary care and internal medicine physicians, and other clinicians who specialize in managing patients with schizophrenia, including nurse practitioners and physician assistants.
Program Overview
After more than 70 years of treating the symptoms of schizophrenia with antipsychotics, it is now known that the hallmark and easily recognizable positive symptoms of schizophrenia — delusions, hearing voices — are often accompanied by equally devastating but less recognized symptoms in the cognitive and negative symptom domains. It’s a flawed but fundamental fact that while effective for some symptoms, traditional antipsychotics (all of which are based on blocking dopamine receptors) are largely inadequate because they don’t address two of the three symptom domains of schizophrenia: cognitive impairment associated with schizophrenia (CIAS) and experiential and expressive negative symptoms. While excessive or dysregulated dopamine is still seen to be fundamental to the pathophysiology of this disease, recent research suggests the key to treating symptoms across all domains may lie in developing therapeutics that target different neurotransmitters. KarXT was recently approved by the FDA, marking a potential paradigm shift in schizophrenia treatment. Additionally, iclepertin is being tested in ongoing phase 3 clinical trials. Most clinicians are unaware of these new treatments' place in the development pipeline and the emerging clinical data. In this Data Dive activity, Dr. Daniel Javitt will review recently published articles and presentations from key psychiatry meetings to give psychiatrists and other clinicians who manage patients with schizophrenia the information they need to understand and use these new and emerging treatments.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Explain the differences between positive, negative, and cognitive symptoms associated with schizophrenia
- Discuss the key neurotransmitters that are thought to be involved in the pathophysiology of negative symptoms and CIAS
- Integrate new and emerging therapeutics into treatment options for schizophrenia based on recent clinical trial findings
Faculty
Daniel C. Javitt, MD, PhD
Professor and Director, Division of Experimental Therapeutics
Director, Schizophrenia Research
Department of Psychiatry
Columbia University Irving Medical Center
New York, New York
Director, Schizophrenia Research
Nathan Kline Institute for Psychiatric Research
Orangeburg, New York
Accreditation Statement
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts Of Interest
Daniel C. Javitt, MD, PhD
Consultant: SK Life Science
Internal Speaker: Boehringer Ingelheim
Major Shareholder: NRx Pharmaceuticals
Monitoring Board Member: Biogen
Directions to Learner
There are no fees for participating and receiving CME credit for this enduring activity. During the period of December 20, 2024 through December 20, 2025, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed posttest with a score of 66% or better and a completed activity evaluation form.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or [email protected].